Products
Vobarilizumab Biosimilar Bispecific Single-Domain Antibody (IL-6R × Albumin) for Research
Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH'), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-625-1mg | 1mg | |
| GMP-Bios-ab-625-10mg | 10mg | |
| GMP-Bios-ab-625-100mg | 100mg | |
| GMP-Bios-ab-625-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH'), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody |
| INN Name | Vobarilizumab |
| Target | IL6R;ALB |
| Format | Bispecific Single Domains (VH-VH') |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Ablynx |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | Nanobody Technology |
About target - IL6R
1. Protein Interleukin-6 receptor subunit alpha
2. Gene IL6R
3. Organism Homo sapiens (Human)
Function
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal (PubMed:28265003).
Signal activation necessitate an association with IL6ST. Activation leads to the regulation of the immune response, acute-phase reactions and hematopoiesis (Probable). The interaction with membrane-bound IL6R and IL6ST stimulates 'classic signaling', the restricted expression of the IL6R limits classic IL6 signaling to only a few tissues such as the liver and some cells of the immune system. Whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).
Isoform 1:
Signaling via the membrane-bound IL6R is mostly regenerative and anti-inflammatory (Probable). Drives naive CD4+ T cells to the Th17 lineage, through 'cluster signaling' by dendritic cells (By similarity).
Isoform 2:
Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity (PubMed:21990364).
The IL6:sIL6R complex (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the proinflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases (PubMed:21990364).
In complex with IL6, is required for induction of VEGF production (PubMed:12794819).
Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity).
'Trans-signaling' in central nervous system regulates energy and glucose homeostasis (By similarity).
Soluble interleukin-6 receptor subunit alpha:
Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity (PubMed:21990364).
The IL6:sIL6R complex (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the proinflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases (PubMed:21990364).
In complex with IL6, is required for induction of VEGF production (PubMed:12794819).
Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity).
'Trans-signaling' in central nervous system regulates energy and glucose homeostasis (By similarity).
Activity regulation
Classic and trans-signaling are both inhibited by tocilizumab, a humanized monoclonal antibody that blocks interleukin IL6R signaling.
